...IBI305 plus chemotherapy in patients with EGFR mutated nonsq
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapyS. LuL. WuH. JianY. ChengQ. WangJ. FangZ. WangY. Hu...